Nuvation Bio Files 8-K on Financials
Ticker: NUVB · Form: 8-K · Filed: Feb 29, 2024 · CIK: 1811063
Sentiment: neutral
Topics: financial-results, 8-K, company-update
Related Tickers: NUVB
TL;DR
Nuvation Bio dropped its 8-K for Feb 29, 2024 - check financials.
AI Summary
Nuvation Bio Inc. filed an 8-K on February 29, 2024, reporting on its results of operations and financial condition. The filing includes financial statements and exhibits. Nuvation Bio Inc. was formerly known as Panacea Acquisition Corp. and changed its name on April 30, 2020.
Why It Matters
This 8-K filing provides an update on Nuvation Bio's financial performance and condition, which is crucial for investors to assess the company's health and future prospects.
Risk Assessment
Risk Level: low — This filing is a routine 8-K reporting financial results and does not indicate any unusual or significant risks.
Key Players & Entities
- Nuvation Bio Inc. (company) — Registrant
- Panacea Acquisition Corp. (company) — Former company name
- February 29, 2024 (date) — Date of earliest event reported
- April 30, 2020 (date) — Date of name change
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report on Nuvation Bio Inc.'s results of operations and financial condition, and to include financial statements and exhibits.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on February 29, 2024.
What was Nuvation Bio Inc.'s former company name?
Nuvation Bio Inc.'s former company name was Panacea Acquisition Corp.
On what date did the company change its name from Panacea Acquisition Corp.?
The company changed its name from Panacea Acquisition Corp. on April 30, 2020.
What is Nuvation Bio Inc.'s principal business address as listed in the filing?
Nuvation Bio Inc.'s principal business address is 1500 Broadway, Suite 1401, New York, NY 10036.
Filing Stats: 508 words · 2 min read · ~2 pages · Grade level 10.2 · Accepted 2024-02-29 16:48:41
Key Financial Figures
- $0.0001 — which registered Class A Common Stock, $0.0001 par value per share NUVB The New Yo
- $11.50 — of Common Stock at an exercise price of $11.50 per share NUVB.WS The New York Stoc
Filing Documents
- d786844d8k.htm (8-K) — 27KB
- d786844dex991.htm (EX-99.1) — 72KB
- g786844g0228225240539.jpg (GRAPHIC) — 4KB
- 0001193125-24-053575.txt ( ) — 271KB
- nuvb-20240229.xsd (EX-101.SCH) — 4KB
- nuvb-20240229_def.xml (EX-101.DEF) — 14KB
- nuvb-20240229_lab.xml (EX-101.LAB) — 23KB
- nuvb-20240229_pre.xml (EX-101.PRE) — 15KB
- d786844d8k_htm.xml (XML) — 6KB
FINANCIAL STATEMENTS AND EXHIBITS
FINANCIAL STATEMENTS AND EXHIBITS (d)Exhibits. Exhibit Number Description 99.1 Press Release of Nuvation Bio Inc. dated February 29, 2024. 104 Cover Page Interactive Data File (embedded within XBRL document) 2
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: February 29, 2024 NUVATION BIO INC. By: /s/ Moses Makunje Name: Moses Makunje Title: VP, Finance, Principal Financial and Accounting Officer 3